Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results

The latest update is out from Aptose Biosciences ( (TSE:APS) ).

Aptose Biosciences announced its second quarter 2025 results, highlighting the progress of its TUSCANY clinical trial for tuspetinib in AML treatment. The trial continues to show promising safety and efficacy, with the Cohort Safety Review Committee recommending a dose escalation to 160 mg. The company also secured a loan agreement with Hanmi Pharmaceutical to support further development and was upgraded to trade on the OTCQB Market, potentially enhancing its market visibility.

The most recent analyst rating on (TSE:APS) stock is a Buy with a C$60.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing innovative therapies for the treatment of acute myeloid leukemia (AML). The company is advancing a tuspetinib-based triple drug frontline therapy aimed at improving outcomes for patients with newly diagnosed AML, particularly those with challenging mutations.

Average Trading Volume: 7,054

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$4.36M

Learn more about APS stock on TipRanks’ Stock Analysis page.